69 drugs reach their earliest generic-entry date in 2033

Jan 2033 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Xatmep methotrexate sodium	methotrexate sodium	Azurity	208400	2 Jan 2033	patent
Zerviate cetirizine hydrochloride	cetirizine hydrochloride	Harrow Eye	208694	9 Jan 2033	patent
Zycubo copper histidinate	copper histidinate	Sentynl Theraps Inc	211241	12 Jan 2033	exclusivity
Complera emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	Gilead Sciences Inc	202123	14 Jan 2033	patent
Scenesse afamelanotide	afamelanotide	Clivunel Inc	210797	20 Jan 2033	patent, carve-out possible
Naftin naftifine hydrochloride	naftifine hydrochloride	Legacy	204286	31 Jan 2033	patent

Feb 2033 · 11

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Baxfendy · 2 strengths baxdrostat	baxdrostat	Astrazeneca Ab	219878	4 Feb 2033	patent
Emblaveo avibactam sodium; aztreonam	avibactam sodium; aztreonam	Abbvie	217906	7 Feb 2033	exclusivity
Seysara · 3 strengths sarecycline hydrochloride	sarecycline hydrochloride	Almirall	209521	9 Feb 2033	patent
Wakix · 2 strengths pitolisant hydrochloride	pitolisant hydrochloride	Harmony	211150	13 Feb 2033	exclusivity
Odefsey emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	Gilead Sciences Inc	208351	15 Feb 2033	patent
Vemlidy tenofovir alafenamide fumarate	tenofovir alafenamide fumarate	Gilead Sciences Inc	208464	15 Feb 2033	patent
Bonjesta doxylamine succinate; pyridoxine hydrochloride	doxylamine succinate; pyridoxine hydrochloride	Duchesnay	209661	18 Feb 2033	patent
Nexterone · 2 strengths amiodarone hydrochloride	amiodarone hydrochloride	Baxter Hlthcare	022325	27 Feb 2033	patent
Orfadin nitisinone	nitisinone	Swedish Orphan	206356	28 Feb 2033	patent
Prevymis · 2 strengths letermovir	letermovir	Merck Sharp Dohme	209940	28 Feb 2033	patent
Qbrexza glycopyrronium tosylate	glycopyrronium tosylate	Journey	210361	28 Feb 2033	patent

Mar 2033 · 9

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Harvoni · 2 strengths ledipasvir; sofosbuvir	ledipasvir; sofosbuvir	Gilead Sciences Inc	212477	14 Mar 2033	patent
Viberzi · 2 strengths eluxadoline	eluxadoline	Abbvie	206940	14 Mar 2033	patent
Bendeka bendamustine hydrochloride	bendamustine hydrochloride	Eagle Pharms	208194	15 Mar 2033	patent, carve-out possible
Esmolol Hydrochloride Double Strength In Plastic Container esmolol hydrochloride	esmolol hydrochloride	Hq Spclt Pharma	205703	15 Mar 2033	patent
Esmolol Hydrochloride In Plastic Container esmolol hydrochloride	esmolol hydrochloride	Hq Spclt Pharma	205703	15 Mar 2033	patent
Phexx citric acid; lactic acid; potassium bitartrate	citric acid; lactic acid; potassium bitartrate	Evofem Inc	208352	15 Mar 2033	patent
Lynavoy linerixibat	linerixibat	Intercept	220295	17 Mar 2033	exclusivity
Qudexy Xr · 5 strengths topiramate	topiramate	Upsher Smith Labs	205122	19 Mar 2033	patent
Xenleta lefamulin acetate	lefamulin acetate	Hong Kong	211672	25 Mar 2033	patent

Apr 2033 · 8

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Genvoya cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	Gilead Sciences Inc	207561	6 Apr 2033	patent
Stribild cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	Gilead Sciences Inc	203100	6 Apr 2033	patent
Rexulti · 5 strengths brexpiprazole	brexpiprazole	Otsuka	205422	12 Apr 2033	patent
Vyxeos cytarabine; daunorubicin	cytarabine; daunorubicin	Jazz Pharms Therap	209401	15 Apr 2033	patent
Truqap · 2 strengths capivasertib	capivasertib	Astrazeneca	218197	16 Apr 2033	patent
Abilify Asimtufii · 2 strengths aripiprazole	aripiprazole	Otsuka	217006	23 Apr 2033	patent
Skyclarys omaveloxolone	omaveloxolone	Biogen Us	216718	24 Apr 2033	patent
Piqray · 3 strengths alpelisib	alpelisib	Novartis	212526	29 Apr 2033	patent

May 2033 · 6

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Kuvan · 2 strengths sapropterin dihydrochloride	sapropterin dihydrochloride	Biomarin Pharm	205065	1 May 2033	patent
Eysuvis loteprednol etabonate	loteprednol etabonate	Alcon Labs Inc	210933	3 May 2033	patent
Inveltys loteprednol etabonate	loteprednol etabonate	Alcon Labs Inc	210565	3 May 2033	patent
Symproic naldemedine tosylate	naldemedine tosylate	Bdsi	208854	13 May 2033	patent
Belsomra · 4 strengths suvorexant	suvorexant	Merck Sharp Dohme	204569	29 May 2033	patent
Aklief trifarotene	trifarotene	Galderma Labs Lp	211527	30 May 2033	patent

Jun 2033 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ibtrozi taletrectinib adipate	taletrectinib adipate	Nuvation	219713	3 Jun 2033	patent
Ultravate halobetasol propionate	halobetasol propionate	Lacer Pharma	208183	19 Jun 2033	patent
Tolsura itraconazole	itraconazole	Mayne Pharma	208901	21 Jun 2033	patent
Vascepa · 2 strengths icosapent ethyl	icosapent ethyl	Amarin Pharms	202057	28 Jun 2033	patent, carve-out possible

Jul 2033 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Cabometyx · 3 strengths cabozantinib s-malate	cabozantinib s-malate	Exelixis Inc	208692	9 Jul 2033	patent

Aug 2033 · 5

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Braftovi encorafenib	encorafenib	Array Biopharma Inc	210496	5 Aug 2033	patent, carve-out possible
Quillichew Er · 3 strengths methylphenidate hydrochloride	methylphenidate hydrochloride	Nextwave Pharms	207960	14 Aug 2033	patent
Mitigare colchicine	colchicine	Hikma	204820	22 Aug 2033	patent, carve-out possible
Kalydeco · 5 strengths ivacaftor	ivacaftor	Vertex Pharms Inc	207925	27 Aug 2033	patent
Esbriet pirfenidone	pirfenidone	Legacy	022535	30 Aug 2033	patent, carve-out possible

Sep 2033 · 7

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Zydelig · 2 strengths idelalisib	idelalisib	Gilead Sciences Inc	205858	2 Sep 2033	patent
Venclexta · 3 strengths venetoclax	venetoclax	Abbvie	208573	6 Sep 2033	patent, carve-out possible
Daptomycin · 2 strengths daptomycin	daptomycin	Hospira	210282	11 Sep 2033	patent
Xyrem sodium oxybate	sodium oxybate	Jazz Pharms	021196	15 Sep 2033	patent
Secuado · 3 strengths asenapine	asenapine	Hisamitsu	212268	22 Sep 2033	patent
Docetaxel · 3 strengths docetaxel	docetaxel	Shilpa	205934	30 Sep 2033	patent
Vanflyta · 2 strengths quizartinib dihydrochloride	quizartinib dihydrochloride	Daiichi Sankyo Inc	216993	30 Sep 2033	patent

Oct 2033 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Veltassa · 3 strengths patiromer sorbitex calcium	patiromer sorbitex calcium	Vifor Pharma	205739	8 Oct 2033	patent, carve-out possible
Mektovi binimetinib	binimetinib	Array Biopharma Inc	210498	18 Oct 2033	patent
Inbrija levodopa	levodopa	Merz	209184	21 Oct 2033	patent, carve-out possible
Vumerity diroximel fumarate	diroximel fumarate	Biogen	211855	29 Oct 2033	patent

Nov 2033 · 5

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Prolensa bromfenac sodium	bromfenac sodium	Bausch And Lomb	203168	11 Nov 2033	patent, carve-out possible
Phenylephrine Hydrochloride · 2 strengths phenylephrine hydrochloride	phenylephrine hydrochloride	Paragon Bioteck	203510	14 Nov 2033	patent, carve-out possible
Aczone dapsone	dapsone	Almirall	207154	18 Nov 2033	patent
Xtoro finafloxacin	finafloxacin	Fonseca Biosciences	206307	21 Nov 2033	patent
Natroba spinosad	spinosad	Cipher	022408	25 Nov 2033	patent, carve-out possible

Dec 2033 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Iclusig · 4 strengths ponatinib hydrochloride	ponatinib hydrochloride	Takeda Pharms Usa	203469	12 Dec 2033	patent
Vybrique · 4 strengths sildenafil citrate	sildenafil citrate	Ibsa	210858	16 Dec 2033	patent
Xiidra lifitegrast	lifitegrast	Bausch And Lomb Inc	208073	18 Dec 2033	patent